Consistent Effects of Canagliflozin (CANA) Across Racial Subgroups of Patients with Type 2 Diabetes Mellitus (T2DM)

被引：0
|
作者：
Gavin, James R., III
Davies, Melanie J.
Davies, Michael
Vija-Purkar, Ujjwala
Alba, Maria
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1095-P
引用
收藏
页码：A285 / A285
页数：1
相关论文
共 50 条
  • [21] Comparison of Hospitalization for Heart Failure (HHF) among Patients with Type 2 Diabetes Mellitus (T2DM) and Macroalbuminuria Initiated on Canagliflozin (CANA) or a DPP-4
    Pilon, Dominic
    Durkin, Michael
    Manceur, Ameur
    Ghelerter, Isabelle
    Lafeuille, Marie-Hel
    Lefebvre, Patrick
    DIABETES, 2020, 69
  • [22] Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks
    Yale, Jean-Francois
    Bakris, George
    Cariou, Bertrand
    Iglesias, Javier Nieto
    Wajs, Ewa
    Figueroa, Katherine
    Jiang, Joel
    Usiskin, Keith
    Meininger, Gary
    DIABETES, 2013, 62 : A277 - A278
  • [23] Efficacy and Safety of Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) and Pioglitazone (PIO) Over 52 Weeks
    Forst, Thomas
    Guthrie, Robert
    Goldenberg, Ronald
    Yee, Jacqueline
    Vijapurkar, Ujjwala
    Meininger, Gary
    Stein, Peter
    DIABETES, 2013, 62 : A284 - A284
  • [24] Quality Measure (QM) Attainment in Overweight/Obese Patients with Type 2 Diabetes (T2DM) Treated with Canagliflozin (CANA) or Sitagliptin (SITA)
    Bailey, Robert
    Vijapurkar, Ujjwala
    Martin, Silas
    Meininger, Gary
    Rupnow, Marcia
    DIABETES, 2014, 63 : A270 - A270
  • [25] Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM) and Presumed Liver Fibrosis Suggestive of Nonalcoholic Steatohepatitis (NASH)
    Polidori, David
    Meininger, Gary
    DIABETES, 2017, 66 : A348 - A348
  • [26] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
    Pititto, L.
    Neslusan, C.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    Asano, E.
    Puig, A.
    VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
  • [27] Efficacy and safety of canagliflozin (CANA) in patients with type 2 diabetes mellitus (T2DM) who progressed to stage 3A chronic kidney disease during treatment
    Roussel, R.
    de Zeeuw, D.
    Law, G.
    Meininger, G.
    DIABETOLOGIA, 2014, 57 : S322 - S323
  • [28] Regional effects of type 2 diabetes mellitus (T2DM) on neurodegeneration
    Moran, C.
    Phan, T. G.
    Beare, R. J.
    Chen, J.
    Blizzard, L.
    Venn, A.
    Greenaway, T.
    Munch, G.
    Forbes, J.
    Pearson, S.
    Srikanth, V
    INTERNATIONAL JOURNAL OF STROKE, 2012, 7 : 20 - 20
  • [29] TIME UNTIL INSULIN INITIATION FOR CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN DUAL AND TRIPLE THERAPY FOR TYPE 2 DIABETES MELLITUS (T2DM) IN IRELAND
    Bacon, T.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    VALUE IN HEALTH, 2015, 18 (03) : A55 - A55
  • [30] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA
    Teschemaker, A. R.
    Neslusan, C.
    Sabapathy, S.
    Yoong, K.
    Johansen, P.
    Willis, M.
    VALUE IN HEALTH, 2015, 18 (03) : A62 - A63
12345